Actualités

Novo Nordisk, the maker of Ozempic, is suing Eli Lilly over advertisements comparing some of their biggest-selling drugs. The ads compare Lilly’s Zepbound with Novo’s Wegovy, and Novo argues they give consumers a misleading picture of how the blockbuster weight-loss drugs stack up. At the center of ...

Eli Lilly's retatrutide meets the primary endpoint in the phase III TRIUMPH-2 & TRIUMPH-3 studies, supporting planned regulatory submissions for obesity in 2027.

The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was up 0.2%, and the actively tra

The legal battle between Novo Nordisk and Eli Lilly is escalating, but analysts are more focused on developments in the lab.

The Danish drugmaker alleges Lilly's advertising misrepresents comparisons between rival obesity treatments.

Novo says Lilly's ads for Zepbound and Mounjaro rely on outdated data and omit newer, higher-dose versions of Wegovy and Ozempic

Friday’s preliminary injunction request escalates legal proceedings initiated earlier this week.

Novo Nordisk is seeking a preliminary U.S. court injunction to immediately block Lilly’s advertisements for Zepbound and Mounjaro, according to a Reuters report on Friday.

Novo Nordisk (NYSE:NVO) has asked a U. S.

Novo Nordisk said it asked a U.S. court to preliminarily halt rival Eli Lilly from advertising weight-loss drugs, days after accusing the Indianapolis drugmaker of using deceptive advertising to mislead consumers in a lawsuit. Friday’s preliminary injunction request, filed in the District of New Jersey, escalates legal proceedings initiated earlier this week. Novo has now asked the court to stop Eli Lilly from advertising its GLP-1 drugs while the lawsuit proceeds.

Novo is seeking an injunction that would halt allegedly “misleading” obesity drug ads. Elsewhere, the FDA began reviewing a highly anticipated medicine and a veteran investor landed at an AI startup.

With yields like this, these undervalued tickers aren't apt to remain this cheap forever.

A 35-year-old institutional powerhouse just made its first move into the ETF market, betting that quality stock picking in developed markets abroad can justify a fee 23 times higher than its cheapest rival.

RHHBY posts 6% constant-currency sales growth in the first half of 2026 as strong demand for key drugs offsets legacy declines, while FDA pipeline progress supports momentum.

Eli Lilly said Thursday it will delay filing for FDA approval of its next-gen weight-loss drug, retatrutide, until the first quarter.

Two more Phase 3 trials showed weight loss above 20%

In recent days, Novo Nordisk filed a federal lawsuit against Eli Lilly, alleging that Lilly’s nationwide advertising for obesity and diabetes drugs like Zepbound and Mounjaro used outdated clinical data and unfair dose comparisons to claim superiority over Novo’s Wegovy and Ozempic. The case raises legal and regulatory questions around drug marketing practices in the high-stakes GLP-1 market, where only a few companies currently compete at scale. Beyond the courtroom, this dispute highlights...

LLY's blockbuster GLP-1 portfolio takes center stage as investors watch Mounjaro, Zepbound and Foundayo for clues to Q2 growth and outlook.

Retatrutide, a once-weekly triple hormone receptor agonist targeting GIP, GLP-1, and glucagon receptors, met the primary endpoint in both the Triumph-2 and Triumph-3 Phase 3 studies.

Novo Nordisk (NVO) closed the most recent trading day at $48.19, moving 2.41% from the previous trading session.

Novo Nordisk just sued Eli Lilly over weight-loss drug ads, but the moment the lawsuit hit, investors moved in exactly the wrong direction for Novo. Here is what the stock reaction reveals about who is actually winning this war.

Novo Nordisk sues LLY over high-profile ads promoting Zepbound and Mounjaro, arguing newer clinical data changes the comparison as the GLP-1 rivalry intensifies.

Jim Cramer is sounding the alarm for investors still riding the AI wave, and his warning carries a specific body count. Here is where he says the smart money is quietly moving before the damage hits.

The Danish pharma giant alleged Lilly misled consumers with false advertising claims that its weight loss drug is superior to Novo’s.

Novo Nordisk’s lawsuit against Eli Lilly (LLY) over alleged misleading GLP-1 advertising has put fresh attention on Lilly’s stock and raised questions about how core obesity and diabetes franchises are being marketed. See our latest analysis for Eli Lilly. Against this legal backdrop, Eli Lilly’s 1-day share price return of 2.49% and 30-day share price return of 6.99% sit within a broader upswing, with a 52.46% 1-year total shareholder return and a very large 5-year total shareholder return...

Novo Nordisk stock has had a tough stretch over the past few years, yet current valuation checks suggest the market may now be pricing it more cautiously than the fundamentals imply. Over the past 3 years, Novo Nordisk has delivered a total shareholder return that is down 35.8%, which puts the recent share price in the context of a material drawdown for long term holders. Expectations around the obesity and diabetes franchise, including products such as Wegovy, sit alongside legal and...

Novo Nordisk is also demanding that Eli Lilly pull its ads and pay damages.

The weight-loss drug wars reached a new level of intensity Tuesday as Novo Nordisk sued Eli Lilly , accusing its arch-rival of misleading advertising.

Healthcare stocks advanced late Tuesday afternoon with the NYSE Healthcare Index rising 0.6% and the

<body><p>STORY: :: Novo Nordisk claims misleading ads in Eli Lilly weight-loss drug lawsuit</p><p>:: July 21, 2026</p><p>:: Maggie Fick, European Pharma Industry Correspondent</p><p>"Novo Nordisk sued rival Eli Lilly in a U.S. federal court on Tuesday, accusing the U.S. drugmaker of false advertising and claiming its weight-loss medicines outperform Novo's drugs." //</p><p>"Novo is alleging in its suit that Lilly's advertisements compare weight-loss results of about 50 pounds for its drug Zepbound with about 33 pounds for Wegovy, even though no head-to-head clinical trial has compared the highest approved doses of the medicines."</p><p>"Pharmaceutical companies regularly sue each other over claims related to patent infringement, for example, but false advertising suits, such as the one filed today, are less common."</p><p>"Novo Nordisk was first to market with its weight-loss injection Wegovy several years ago, but it later lost the lead to Eli Lilly, after that company launched a rival injection called Zepbound in the United States. Last year, Novo replaced its CEO and was forced to issue multiple profit warnings as it fell further behind Eli Lilly in this really competitive and booming obesity drug market, which analysts expect to be worth more than $100 billion by 2030. This year, Novo has actually sort of landed a counterpunch with its oral Wegovy pill. It was able to launch that drug ahead of Eli Lilly. Lilly has, in April, launched its own pill, a weight-loss pill. But Novo has managed to keep up strong sales even since the launch of Lilly's pill."</p><p>"Both companies report quarterly results in the next couple of weeks."</p><p>:: Novo Nordisk</p><p>:: Eli Lilly</p><p>The Danish company filed the lawsuit in U.S. District Court ‌in New Jersey, alleging Lilly violated federal and state false advertising and unfair competition laws, including the Lanham Act, through nationwide advertising campaigns for obesity drug Zepbound and diabetes treatment Mounjaro.</p><p>Novo alleges Lilly compared the highest approved doses of its medicines with lower doses of Novo's Wegovy and Ozempic while omitting newer, higher-dose versions that Novo says deliver greater weight loss.</p><p>But Indianapolis-based Eli Lilly said it stands firmly behind its ads, which are based on the results of its SURMOUNT-5 trial. That ⁠trial — completed in 2024 — compared patients on 10 mg or 15 mg of Lilly's Zepbound to patients on 1.7 mg or 2.4 mg doses of Wegovy. The FDA approved ​a 7.2 mg dose of Wegovy in March of this year.</p></body>